Gain Therapeutics
GANX
22 hedge funds and large institutions have $5.54M invested in Gain Therapeutics in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.
2,527% more call options, than puts
Call options by funds: $289K | Put options by funds: $11K
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
48% more capital invested
Capital invested by funds: $3.74M → $5.54M (+$1.8M)
10% more funds holding
Funds holding: 20 → 22 (+2)
0.38% less ownership
Funds ownership: 10.06% → 9.68% (-0.38%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$215K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$71.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$62K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$42.9K |
| 5 |
Renaissance Technologies
New York
|
+$22.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
-$81.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$39.9K |
| 3 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
-$25.5K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$16.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12.2K |
GANX Hedge Fund Activity: Q1 2023 in Review
22 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2023, worth a combined $5.54M — up 48% from $3.74M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GANX positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $215K. The largest seller was CM Management, cutting an estimated $81.7K.
- 22 institutional investors held Gain Therapeutics (GANX) as of Q1 2023, up from 20 in Q4 2022.
- Funds reported $5.54M of Gain Therapeutics stock for Q1 2023, up 48% quarter-over-quarter.
- 5 funds opened new Gain Therapeutics positions in Q1 2023 and 2 closed out, a net change of +3 holders.
- The largest Gain Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $215K added.
- The largest Gain Therapeutics seller in Q1 2023 was CM Management, an estimated $81.7K sold.
Based on aggregated 13F filings for Q1 2023.